Skip to main content
OpenTrials

Clinical trial condition

Primary Progressive Multiple Sclerosis

Explore clinical trials studying Primary Progressive Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

27 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Primary Progressive Multiple Sclerosis trial results

Active, not recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

NCT04688788

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +13 more
Locations
  • Danish Multiple Sclerosis Center, Rigshospitalet Glostrup Municipality, Copenhagen, Denmark
  • Department of Neurology, Aalborg University Hospital Aalborg, Denmark
  • Department of Neurology, Aarhus University Hospital Aarhus, Denmark
  • Department of Neurology, Hospital of South West Jutland, Esbjerg Esbjerg, Denmark
View Trial Details
Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +11 more
Locations
  • The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China
  • Peking Union Medical College Hospital Beijing, China
  • Peking University First Hospital Beijing, China
  • Beijing Hospital of Ministry of Health Beijing, China
View all 17 locations
View Trial Details
Active, not recruiting

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

NCT05893225

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Brain Diseases, +16 more
Locations
  • AZ Sint-Jan Brugge Bruges, Belgium
  • Antwerp University Hospital Edegem, Belgium
  • University Hospital Ghent Ghent, Belgium
  • National MS Center Melsbroek Melsbroek, Belgium
View Trial Details
Completed

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +11 more
Locations
  • Neurology Associates PA Maitland, Florida, United States
  • University of South Florida Tampa, Florida, United States
  • Johns Hopkins Hospital Baltimore, Maryland, United States
  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis Owosso, Michigan, United States
View all 37 locations
View Trial Details

Related conditions